| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RHINO BIOTECH Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BEAM THERAPEUTICS | 23,150 | 0,00 % | Beam Therapeutics GAAP EPS of -$1.10 misses by $0.09, revenue of $9.69M misses by $3.03M | ||
| DYNE THERAPEUTICS | 18,205 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,78 | 0,00 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| NUVALENT | 95,87 | +4,21 % | Nuvalent to present zidesamtinib patient data at lung cancer conference | ||
| ADMA BIOLOGICS | 14,030 | 0,00 % | ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales | ||
| AMYLYX PHARMACEUTICALS | 12,460 | 0,00 % | Amylyx targets avexitide launch in 2027 with recruitment completion for LUCIDITY now expected in Q1 2026 | ||
| RECURSION PHARMACEUTICALS | 4,605 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| EVOTEC | 5,556 | 0,00 % | EQS-News: Evotec SE: In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen | EQS-News: Evotec SE
/ Schlagwort(e): Vereinbarung
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,140 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology | ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 3,920 | 0,00 % | Taysha Gene Therapies: Citizens hebt Kursziel auf 8 US-Dollar an | ||
| MONTE ROSA THERAPEUTICS | 13,010 | 0,00 % | Monte Rosa Therapeutics reports Q3 results | ||
| PRAXIS PRECISION MEDICINES | 172,03 | 0,00 % | Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline | ||
| KINIKSA PHARMACEUTICALS | 38,630 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 25,200 | 0,00 % | Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results | ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology... ► Artikel lesen | |
| KEROS THERAPEUTICS | 16,180 | +3,49 % | Keros Therapeutics, Inc. - 10-Q, Quarterly Report |